FDA AdComm Gives Thumbs Up To Pfizer’s RSV Vaccine Candidate For Elderly People
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of Pfizer Inc’s (NYSE:PFE) available data is adequate to…
FDA Rejects Cytokinetics’ Heart Failure Treatment Candidate
The FDA issued a Complete Response Letter to Cytokinetics Incorporated’s (NASDAQ:CYTK) omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for…
FDA Approves Regeneron-Sanofi’s Sarilumab As First Biologic For Stiffness, Pain In Muscles
The FDA approved Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The approval…
Atyr Pharma’s Efzofitimod Has Received FDA For Systemic Sclerosis (SSc) And Fast Track Designation For SSc-Associated Interstitial Lung Disease (SSc-ILD); Proof-of-concept Study In SSc-ILD Expected To Begin In 2023
The Phase 2 study is expected to be a randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety and tolerability of efzofitimod in patients with SSc-ILD. This is expected to be
Novavax Ushers New CEO On Uncertainty Concerns, Says It Needs To Work On Competitive COVID-19 Product
COVID-19 vaccine maker Novavax Inc (NASDAQ: NVAX) shares plunged after it
Novocure Has Enrolled The Final Patient In The Pivotal METIS Study Evaluating The Efficacy Of Tumor Treating Fields (TT Fields) Therapy Following Stereotactic Radiosurgery For Brain Metastases Resulting From Non-small Cell Lung Cancer
Following the completion of enrollment, patients will be followed for a minimum of 12 months.
Why Reata Pharma Shares Are Skyrocketing Today
The FDA approved Reata Pharmaceuticals Inc’s (NASDAQ:RETA) Skyclarys (omaveloxolone) for Friedreich’s ataxia in adults and adolescents aged 16 and older. With…
Reported Late Tuesday Feb. 28, Regeneron Pharmaceuticals And Sanofi Announce Kevzara Approved By FDA As First And Only Biologic Indicated For Patients With Polymyalgia Rheumatica
Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial
Kevzara now approved to treat two chronic inflammatory disorders
TARRYTOWN, N.Y. and CAMBRIDGE,
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
Guggenheim Partners initiated coverage on Structure Therapeutics Inc (NASDAQ:GPCR) with a Buy rating and a price target of $50 based on the multi-billion-dollar…
Revolution Medicines’ Early-Data Validation For Cancer Program Wins Price Target Boost By This Analyst
Needham increased the price target for Revolution Medicines Inc (NASDAQ:RVMD) from $32 to $38 with a Buy rating. In its Q4 earnings release, Revolution…